Cellectis S.A. - ADR Peer Comparison

$1.09

$0.06 (5.31%)

As on 03-Nov-2026 16:00EST

Market cap

$109 Mln

Revenue (TTM)

$57 Mln

P/E Ratio

--

P/B Ratio

2.8

Div. Yield

0 %

Edit

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Market cap ($ Mln)	109	2,740	2,286	1,969	1,229
Revenue ($ Mln)	57	450	549	121	1
Net Profit ($ Mln)	-65.35	-188.21	17.88	-57.76	-59.95
Net Margin (%)	-115.48	-41.86	3.26	-47.60	-9,759.23
RoE (%)	-111.74	-28.46	1.43	-9.91	-118.98
Price to Earnings	--	--	131.50	--	--
Price-To-Book	2.82	4.52	1.82	3.58	32.01

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Operating Revenue	56.59	449.61	549.12	120.79	0.61
Cost of Revenue	14.31	195.71	548.01	19.21	0.30
Gross Profit	63.15	269.08	212.72	12.07	0.34
Operating Expenses	104.13	517.90	35.89	154.86	67.15
Operating Profit (EBIT)	-61.86	-264.00	-34.78	-118.11	-66.84
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-69.15	-190.72	20.08	-57.14	-59.95
Provision for Tax	-3.80	-2.51	1.66	0.62	0.00
Profit after Tax (Net Income)	-65.35	-188.21	17.88	-57.50	-59.95
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Shareholder's Funds	41.07	607.04	1,260.78	568.41	38.47
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	91.34	39.17	186.25	123.56	55.23
Current Liabilities	134.96	428.58	275.21	81.11	12.71
Total Liabilities	324.72	1,172.38	1,753.10	784.68	131.44

Assets ($ Mln)

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Non-Current Assets	82.95	160.76	183.02	575.59	12.13
Current Assets	184.42	914.04	1,553.41	197.49	94.28
Total Assets	324.72	1,172.38	1,753.10	784.68	131.44
Total Debt*	84.57	254.58	94.51	127.33	0.11
Net Current Assets	49.46	485.45	0.00	116.38	81.57

Cashflow ($ Mln)

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Cash From Operating Activities	-40.14	-150.79	-64.66	-49.95	-62.27
Cash Flow from Investing Activities	-29.58	307.87	-29.41	0.12	-47.99
Cash from Financing Activities	-16.20	72.35	7.84	147.34	0.02
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
ROCE (%)	-32.32	-18.15	41.92	-15.42	-104.49
ROE (%)	-111.74	-28.46	1.43	-10.06	-118.98
ROA (%)	-14.15	-12.55	0.66	-6.60	-40.08
EBIT Margin (%)	-131.76	-41.09	-6.33	-42.43	-9,892.63
Net Margin (%)	-115.48	-41.86	3.26	-47.60	-9,759.23
Cash Profit Margin (%)	0.00	0.00	--	--	-0.02

Growth Ratios

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Revenue Growth (%)	0.52	5.10	-8.81	602.33	-97.63
EBIT Growth (%)	-46.93	11.36	-76.55	17.93	26.29
Net Profit Growth (%)	-10.76	11.44	-96.17	43.71	31.30
EPS Growth (%)	-10.45	-1.87	-96.17	47.43	31.24
Book Value Growth (%)	-57.85	-25.05	2.54	-6.65	-59.14

Valuation Ratios

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Price / Earnings	-7.18	-11.11	5.08	-13.58	-1.08
Price / Book Value	6.40	2.73	1.88	2.32	1.54
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-9.96	-9.39	-25.56	-18.38	-0.12
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Debt to Equity	1.28	0.00	0.00	0.19	0.00
Short term debt to equity ratio	0.20	0.40	0.02	0.02	0.00
Current Ratio	1.37	2.13	5.64	2.43	7.42
Quick Ratio	1.37	1.92	5.50	2.09	7.42
Interest Coverage	-7.21	-30.87	-19.05	-4.06	--

Operating Efficiency Ratios

	Cellectis S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Debtors to sales (%)	24.11	16.23	21.41	47.25	1,512.64
Asset Turnover	0.12	0.30	0.20	0.14	0.00
Receivable days	121.05	77.60	104.79	380.35	8,295.02
Inventory Days	--	109.55	49.57	791.94	--
Payable days	669.97	231.78	47.68	931.00	6,253.37
Cash Conversion Cycle	--	-44.63	106.67	241.30	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly